Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule

Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.

Pricing Strategies Market Access

Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach

Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions or else.

Pricing Debate Policy & Regulation

Value-Based Contracts Getting More Safe Harbor Attention From OIG

But so far, OIG has declined a blanket safe harbor for proposed value-based payments, saying it still wants to consider proposals case-by-case. Discussions between the office and stakeholders are continuing, Bristol-Myers Squibb's Mike Ryan says.

Pricing Strategies Medicare

US Retail Drug Spending Growth Slows Substantially In 2016

Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.

Pricing Debate Reimbursement

Copay Charity Assistance Advisory Rescinded Over Patient Steering Concerns

US OIG's first-ever rescission means the advisory is revoked retroactively to its date of issue, which could lead to anti-kickback enforcement actions against behavior by the charity and manufacturer donors since then. 

Compliance Medicare

Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B

Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.

Pricing Debate Medicare
See All
Advertisement
UsernamePublicRestriction

Register